Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 diabetes. The decision comes after an international clinical trial found the risk of deteriorating kidney function was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. Katherine Ward has this story and more in Health Matters for Tuesday Aug. 19, 2025.Â
Health Matters
Health Matters: Health Canada approves Ozempic to help reduce kidney decline
More Videos
-
Health Matters: CMA asks government to remove interprovincial barriers
-
Health Matters: Health Canada expands power bank recall
-
Health Matters: Kate, Princess of Wales, warns screen time feeds disconnection
-
Health Matters: Ontario hospitals ask for an additional $1.1B in funding
-
Health Matters: Barrhaven Market brand organic pistachio kernels recalled
-
Health Matters: CFIA expands pistachio recall
You are viewing an .
View Original Article